Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
HCG clinicians contributing to one of the largest bodies of oncology research from India
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated